Bioinformatics Disease RNA 
The Open Targets Blog
JANUARY 30, 2025
“Sam has an exceptional talent in software engineering, and his contributions reflect a deep understanding of both the technical and biological aspects required for bioinformatics tool development,” says Laura Luebbert, now a postdoctoral fellow in the Sabeti lab at the Broad Institute of MIT and Harvard and Harvard University.
Elrig
MARCH 25, 2025
This second ELRIG meeting on Therapeutic Oligonucleotides brings together esteemed scientists from academia, industry, and other members of the drug discovery community to explore the discovery, validation, and targeting of oligonucleotide-based drug candidates, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
DECEMBER 6, 2024
This includes verifying the experimental design and understanding how the data was generated whether it was from RNA sequencing, mass spectrometry, or other biological assays. Figure 1: High-level workflow for early drug discovery Once the raw data has been gathered, the next step is to gain a thorough understanding of the data.
Drug Target Review
JULY 24, 2023
Through phylogenetic analysis and microscopy techniques, they identified a nuclear-encoded apicoplast RNA polymerase σ subunit called ApSigma. The study suggests that this regulatory system could be a potential target for future malaria treatments, offering hope for combatting this deadly disease that affects millions worldwide.
PLOS: DNA Science
MAY 16, 2024
These factors are converging to enable both identification of novel infectious diseases as well as microbial resistance, before these threats can impact public health, write a team from the European Society for Clinical Microbiology and Infectious Diseases in Frontiers in Science. COVID clearly caught us off guard.
Elrig
APRIL 29, 2024
With a background in Bioinformatics and Computational Biology, she has a keen interest in using technology to solve problems in healthcare and medicine. She has played a key role inbuilding the target identification platform and a proprietary database of transcriptome-wide, functional RNA structures.
Vial
DECEMBER 5, 2023
Among others, NGS has led to the identification of disease-causing variants and novel drug targets and an improved understanding of complex biological events, e.g., the heterogeneity of tumors. Methods of analysis include whole-genome sequencing (WGS), whole-exome sequencing (WES), and targeted sequencing.
Expert insights. Personalized for you.
76 
Let's personalize your content